<DOC>
	<DOCNO>NCT00265655</DOCNO>
	<brief_summary>To determine objective response rate ( ORR ) oral satraplatin patient Metastatic Breast Cancer .</brief_summary>
	<brief_title>Satraplatin Patients With Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>This Phase II open label , nonrandomized study patient metastatic breast cancer . WHAT IS SATRAPLATIN : Satraplatin member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>1 . Has cytologically pathologically confirm breast cancer metastatic 2 . Must prior Herceptin√í therapy patient HER2+ ( overexpressing ) breast cancer . HER2 consider overexpressed 3+ IHC gene amplify Flourescence situ hybridization ( FISH ) 3 . Has 1 prior chemotherapy regimen MBC 4 . Has prior platinumbased therapy 5 . Has ECOG Performance Status ( PS ) 02</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>